Clinical trials: Liraglutide
Type2diabetes
Real-World Evaluation of Omarigliptin for Type 2 Diabetes Meliitus in Bangladesh
The study titled "Efficacy and Safety of Omarigliptin, A Weekly Dipeptidyl Peptidase-4 Inhibitor for Type 2 Diabetes Management: Real-World Evaluation in Bangladesh" aims to assess the real-world effectiveness and safety of…
- Trial name
- NCT06449235
- Testing
- Omarigliptin, Sulphonylureas, Metformin
- Where
- Bangladesh
- Volunteers
- 938 people
- Sponsor
- Bangladesh Institute of Research and Rehabilitation in Diabetes, Endocrine and Metabolic Disorders
Diabetes, Diabetes Mellitus, Type 1
The Efficacy and Safety of Liraglutide as Adjunct Therapy to Insulin in the Treatment of Type 1 Diabetes
This trial is conducted globally. The aim of the trial is to confirm the efficacy and safety of liraglutide as adjunct therapy to insulin in the treatment of type 1 diabetes.
- Trial name
- ADJUNCT ONE™ (NCT01836523)
- Testing
- liraglutide
- Where
- 182 sites in United States, Argentina and 15 more
- Volunteers
- 1,398 people
- Sponsor
- Novo Nordisk A/S
Diabetic Kidney Disease
The Effect of Glucagon-like-peptide 1 (GLP-1) Receptor Agonism on Diabetic Kidney Disease
Diabetic kidney disease (DKD) is a devastating complication of diabetes, that in it's worst form, can lead to early cardiovascular death or kidney failure.
- Trial name
- NCT01847313
- Testing
- Liraglutide
- Where
- Ireland
- Volunteers
- 20 people
- Sponsor
- Karl Neff
Obesity & Overweight, Diabetes (DM)
Determination of Resistance Training Status for Patients on Glucagon-Like Peptide-1 Receptor Agonists
This study examines how adults who take a GLP-1 receptor agonist medication (such as semaglutide [Ozempic, Wegovy, Rybelsus], liraglutide [Saxenda, Victoza], or tirzepatide [Mounjaro, Zepbound]) perform resistance (strength)…
- Trial name
- NCT07702461
- Testing
- Glucagon-Like Peptide-1 Agonist (GLP-1)
- Where
- United States
- Volunteers
- 300 people
- Sponsor
- Ohio State University
Type 1 Diabetes
Effects of Single Doses of Liraglutide and Dapagliflozin on Ketogenesis in Type 1 Diabetes
1. To compare levels of ketone bodies (beta-hydroxybutyrate and acetoacetate) in plasma and urine following a single dose treatment of either liraglutide 1.8mg, dapagliflozin 10mg or placebo in insulinopenic state. 2.
- Trial name
- 1974 (NCT02777073)
- Testing
- Victoza, Dapagliflozin 10mg Tab
- Where
- United States
- Volunteers
- 43 people
- Sponsor
- University at Buffalo
Diabetes
Replication of the LEAD-2 Diabetes Trial in Healthcare Claims Data
Investigators are building an empirical evidence base for real world data through large-scale replication of randomized controlled trials.
- Trial name
- NCT05162183
- Testing
- Glimepiride, Liraglutide
- Where
- United States
- Volunteers
- 3,474 people
- Sponsor
- Brigham and Women's Hospital
Obesity
Weight Loss With Intensive Lifestyle Modifications Plus Bariatric Surgery Versus Liraglutide 3 mg
Background/Objectives: Only 1% of the clinically eligible subjects receive surgical treatment for their obesity, thus other options should be investigated.
- Trial name
- LETHE (NCT03534310)
- Testing
- LIRAGLUTIDE 3 Mg/0.5 mL (18 Mg/3 mL) SUB-Q PEN INJECTOR (ML), lifestyle modification, sleeve gastrectomy
- Where
- Italy
- Volunteers
- 75 people
- Sponsor
- Catholic University of the Sacred Heart
Diabetes Mellitus
Effect of GLP-1 on Insulin-dose, Risk of Hypoglycemia and Gastric Emptying Rate in Patients With Type 1 Diabetes
The aim of the study is to investigate the effect of Victoza (a GLP-1 receptor agonist)on insulin-dose, risk of hypoglycemia and gastric emptying rate during hypoglycemia in patients with type 1 diabetes.
- Trial name
- NCT00993720
- Testing
- Liraglutide, continuous insulin therapy
- Where
- Denmark
- Volunteers
- 30 people
- Sponsor
- Hvidovre University Hospital
Diabetes, Diabetes Mellitus, Type 2
The Efficacy and Safety of Liraglutide Compared to Sitagliptin, Both in Combination With Metformin in Chinese Subjects With Type 2 Diabetes
This trial is conducted in Asia. The aim of this trial is to investigate the efficacy and safety of liraglutide compared to sitagliptin, both as add-on to metformin in Chinese subjects with type 2 diabetes inadequately controlled…
- Trial name
- NCT02008682
- Testing
- liraglutide, sitagliptin
- Where
- 25 sites in China
- Volunteers
- 368 people
- Sponsor
- Novo Nordisk A/S
Diabetes Mellitus, Type 2
Incretin-based Drugs and Pancreatic Cancer
The purpose of this study is to determine whether incretin-based drugs (used to treat type 2 diabetes) taken either alone in or combination with other anti-diabetic drugs are associated with an increased risk of pancreatic cancer…
- Trial name
- NCT02475499
- Testing
- DPP-4 inhibitors, GLP-1 analogs, Sulfonylureas
- Where
- Canada
- Volunteers
- 886,172 people
- Sponsor
- Canadian Network for Observational Drug Effect Studies, CNODES
Polycystic Ovary Syndrome (PCOS), Overweight
The Effect of GLP-1 Agonists Versus OCs on Reproductive Disorders and Cardiovascular Risks in Overweight PCOS
Polycystic ovary syndrome (PCOS) is a health problem that affects one in 10 women of childbearing age, which is usually characterized by hormonal imbalance and metabolism problems such as hyperandrogenism and obesity.
- Conditions
- Polycystic Ovary Syndrome (PCOS), Overweight, Obesity
- Trial name
- NCT03151005
- Testing
- Metformin-GLP-1 Receptor Agonist, Metformin-Oral Contraceptive(OC)
- Where
- China
- Volunteers
- 70 people
- Sponsor
- Xinqiao Hospital of Chongqing
Obesity
Evaluation of Liraglutide 3.0mg in Patients With Poor Weight-loss and a Suboptimal Glucagon-like Peptide-1 Response
A double-blinded, randomised, placebo-controlled trial of liraglutide 3.0 mg in patients with poor weight-loss and a suboptimal glucagon-like peptide-1 response following bariatric surgery
- Trial name
- BARIOPTIMISE (NCT03341429)
- Testing
- Liraglutide Pen Injector [Saxenda]
- Where
- United Kingdom
- Volunteers
- 70 people
- Sponsor
- University College, London
Diabetes, Diabetes Mellitus, Type 2
Effect of Liraglutide on Glucagon Secretion in Subjects With Type 2 Diabetes
This trial is conducted in Europe. The aim of this trial is to examine the effect of NNC 90-1170 on the hypoglycaemic counterregulation in subjects with type 2 diabetes.
- Trial name
- NCT01509742
- Testing
- liraglutide
- Where
- Germany
- Volunteers
- 19 people
- Sponsor
- Novo Nordisk A/S
Obesity or Overweight
A Research Study About Weight Loss and Treatment Patterns With the Use of Saxenda® in Adults in Real-life Settings in Switzerland
The study is investigating weight loss and treatment patterns associated with the use of Saxenda® in adult patients. The aim of the study is to assess the weight loss associated with Saxenda® in patients with obesity or…
- Trial name
- NCT05153590
- Testing
- Saxenda®
- Where
- Denmark
- Volunteers
- 269 people
- Sponsor
- Novo Nordisk A/S
Obesity
Reward Mechanisms in Obesity
The study aims to investigate the effects of 3.0 mg of liraglutide on reward brain circuits in human obesity and to better understand its effects on weight loss (in patients without diabetes).
- Trial name
- LIRAOB (NCT03347890)
- Where
- Switzerland
- Volunteers
- 70 people, healthy volunteers welcome
- Sponsor
- Zoltan Pataky
Diabetes Mellitus, Type 2
A Study Using Medical Records of Danish People With Type 2 Diabetes Comparing Empagliflozin and Glucagon-Like Peptide-1 Receptor Agonists (GLP1-RA) in the Occurrence of Serious Cardiovascular Outcomes
The primary research question is to evaluate whether, among patients with type 2 diabetes mellitus (T2D), initiation of empagliflozin changes the adjusted incidence of outcomes compared with initiation of Glucagon-Like Peptide-1…
- Trial name
- NCT03993132
- Testing
- Empagliflozin, Liraglutide
- Where
- Denmark
- Volunteers
- 26,774 people
- Sponsor
- Boehringer Ingelheim
Maturity Onset Diabetes of the Young
Liraglutide Treatment in Patients With Maturity-onset Diabetes of the Young (MODY)
The reason for this research study is to better understand the use of liraglutide, a commonly prescribed Type 2 diabetes medication, in patients with a diagnosis of maturity-onset diabetes of the young (MODY).
- Trial name
- NCT07029009
- Testing
- Liraglutide
- Where
- United States
- Volunteers
- 50 people
- Sponsor
- Mansa
Type 2 Diabetes
GLP-1 and Microvascular Function in Type 2 Diabetes
Some gut hormones, called incretins, stimulate insulin production in order to control sugar levels but also activate brain centres and signal to stop eating.
- Trial name
- GLP-1ADDS (NCT01740921)
- Testing
- Liraglutide, diet, Aspirin
- Where
- United Kingdom
- Volunteers
- 39 people
- Sponsor
- Royal Devon and Exeter NHS Foundation Trust
Diabetes Mellitus, Type 2, Diabetes Mellitus, Type II
Effect of Liraglutide (Victoza) on Inflammation in Human Adipose Tissue and Blood
The objective of this study is to test the hypothesis that liraglutide (commonly known as Victoza) can promote an anti-inflammatory macrophage phenotype in human adipose tissue and blood, thereby reducing localized and systemic…
- Conditions
- Diabetes Mellitus, Type 2, Diabetes Mellitus, Type II, Diabetes Mellitus, Adult-Onset, Inflammation
- Trial name
- NCT02650206
- Testing
- Victoza (liraglutide) with dietician monitoring
- Where
- United States
- Volunteers
- 56 people
- Sponsor
- Stanford University
Binge Eating Behaviour
Influence of Appetite Related Hormones in Binge Eating Behaviour Among the Overweight and Obese
Malaysia has increasing challenges in lifestyle related diseases, which is related to eating habits and disorders. According to the National Health \& Morbidity Survey in 2011; it was reported the prevalence of obesity is 15.1%…
- Trial name
- NCT01739049
- Testing
- Liraglutide, Diet and Exercise
- Where
- Malaysia
- Volunteers
- 42 people, healthy volunteers welcome
- Sponsor
- Universiti Kebangsaan Malaysia Medical Centre